Equities
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.

  • Revenue in USD (TTM)99.68bn
  • Net income in USD30.23bn
  • Incorporated1942
  • Employees79.00k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
announced
Transaction
value
Global Blood Therapeutics IncDeal completed08 Aug 202208 Aug 2022Deal completed5.45%5.07bn
Biohaven Pharmaceutical Holding Co LtdDeal completed10 May 202210 May 2022Deal completed6.82%12.60bn
ReViral LtdDeal completed07 Apr 202207 Apr 2022Deal completed-1.73%525.00m
Arena Pharmaceuticals IncDeal completed13 Dec 202113 Dec 2021Deal completed-1.56%6.68bn
Data delayed at least 15 minutes, as of Dec 09 2022 17:27 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Amgen, Inc.26.33bn6.84bn152.37bn24.20k22.8841.7114.955.7912.4812.4848.096.850.40921.435.221,088,017.0010.6211.0713.7413.4075.7879.2925.9630.881.357.700.913849.282.182.47-18.87-5.261.0111.97
Bristol-Myers Squibb Co46.74bn6.68bn169.84bn32.20k26.045.199.983.633.073.0721.5315.380.44714.655.721,451,491.006.402.677.943.2978.9174.1814.326.541.314.490.5443163.849.0919.01177.589.43-4.355.22
Merck & Co Inc58.97bn15.32bn281.05bn68.00k18.366.3214.654.776.046.0123.2317.550.5883.066.53867,264.7015.297.6119.9510.1470.8570.9226.0016.061.2210.490.405986.0617.314.12173.1825.7922.487.49
Pfizer Inc.99.68bn30.23bn290.66bn79.00k9.823.148.292.925.275.1917.3716.510.53233.797.131,261,722.0016.156.6221.018.2565.5174.0430.3521.321.3716.560.28375.7295.169.00238.0525.516.285.39
AbbVie Inc57.82bn13.34bn293.55bn50.00k22.1118.3513.525.087.517.5132.549.040.39855.325.771,156,380.009.257.4611.739.4671.1672.0323.2118.110.83138.810.812897.8922.6916.99151.7114.1310.4417.93
Eli Lilly And Co29.24bn6.03bn353.27bn35.00k55.8735.0846.3212.086.656.6532.2710.600.61141.844.63835,414.3012.6211.0818.2815.8075.6177.1620.6320.770.88228.190.609853.7515.405.94-9.8815.3111.4010.76
Data as of Dec 09 2022. Currency figures normalised to Pfizer Inc's reporting currency: US Dollar USD

Institutional shareholders

33.07%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2022470.11m8.38%
SSgA Funds Management, Inc.as of 30 Sep 2022287.61m5.13%
BlackRock Fund Advisorsas of 30 Sep 2022286.19m5.10%
Capital Research & Management Co. (World Investors)as of 30 Sep 2022248.85m4.43%
Wellington Management Co. LLPas of 30 Sep 2022210.87m3.76%
Geode Capital Management LLCas of 30 Sep 2022110.44m1.97%
Charles Schwab Investment Management, Inc.as of 30 Sep 202270.12m1.25%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202259.73m1.06%
Norges Bank Investment Managementas of 31 Dec 202156.76m1.01%
Capital Research & Management Co. (International Investors)as of 30 Sep 202255.32m0.99%
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.